Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | BCDIN3D | Q7Z5W3 | 10/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313811 | 0.92 | MAPT (0.51) | EGFRKDRMAPTLMNABCDIN3D | |
| SCHEMBL10275464 | 0.90 | EGFR (0.42) | EGFRPDGFRBKDRMAPTLMNA | |
| SCHEMBL10275611 | 0.83 | MAPK14 (0.51) | KDRMAPTLMNABCDIN3DXDH | |
| SCHEMBL10276071 | 0.78 | EGFR (0.43) | EGFRPDGFRBKDRDHODH | |
| SCHEMBL10275527 | 0.78 | SYK (0.41) | MAPTLMNABCDIN3D | |
| SCHEMBL10313812 | 0.76 | XDH (0.42) | KDRMAPTLMNAPDE2AXDH | |
| SCHEMBL12826210 | 0.74 | EGFR (0.49) | EGFRPDGFRBKDRDHODH | |
| SCHEMBL5007643 | 0.73 | XDH (0.64) | EGFRXDH | |
| SCHEMBL10276387 | 0.72 | XDH (0.53) | KDRXDH | |
| SCHEMBL10276254 | 0.70 | TSHR (0.54) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | EGFR 2811/4885PDGFRB 4339/4885KDR 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.